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Abstract 
The antiplatelet efficacy of aspirin (ASA) is reduced in type 2 diabetes (T2D). As the best ex-
vivo method of measuring ASA efficacy remains uncertain, we compared nine platelet 
function tests to assess responsiveness to 3 ASA dosing regimens in 24 T2D patients 
randomized in a 3-treatment crossover design to ASA 100 mg/day, 200 mg/day or 100 mg 
twice daily for 2-week treatment periods. Platelet function tests compared were: Light 
transmission aggregometry (LTA-0.5mg/ml of arachidonic acid (AA) and 10 µM ADP); 
Multiplate whole blood aggregometry (WBA-0.5mM AA and 6.5µM ADP); PFA-100TM-CADP 
and CEPI; VerifyNowTM-ASA; Urinary 11-dehydro-thromboxane B2 (TxB2) and Serum TxB2. All 
cyclo-oxygenase (COX-1) dependent tests and some COX-1 independent tests (PFA-CEPI, LTA-
ADP) demonstrated significant reductions in platelet reactivity with all ASA doses. Two COX-
1 independent tests (WBA-ADP and PFA-CADP) showed no overall reduction in platelet 
reactivity. Overall classifications for detecting all ASA doses, compared to baseline, were: Very 
good-LTA-AA (k=0.95) and VerifyNowTM-ASA (k=0.85); Good-Serum TxB2 (k=0.79); Moderate-
LTA-ADP (k=0.59), PFA-100TM-CEPI (k=0.56), Urinary TxB2 (k=0.55), WBA-AA (k=0.47); Poor-
PFA-100TM-CADP (k=-0.02) and WBA-ADP (k=-0.07). No significant kappa statistic differences 
were seen for each test for each ASA dose. Correlations for each test with serum TxB2 
measurements were: Very good - VerifyNowTM-ASA (k=0.81, R2=0.56), LTA-AA (k=0.85, 
R2=0.65); Good-PFA-100TM-CEPI (k=0.62, R2=0.30); Moderate-Urinary TxB2 (k=0.57, R2=0.51), 
LTA-ADP (k=0.47, R2=0.56); Fair-WBA-AA (k=0.31, R2=0.31) and Poor-PFA-100TM-CADP 
(k=0.04, R2=0.003), WBA-ADP (k=-0.04, R2=0.0005). The platelet function tests we assessed 
were not equally effective in measuring the antiplatelet effect of ASA, and correlated poorly 
amongst themselves but COX-1 dependent tests performed better than non-COX-1 
dependent tests. 
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Introduction 
Reduced efficacy of aspirin (ASA) to inhibit platelet aggregation is observed frequently in type 
2 diabetes (T2D), compared with the general population, and has been referred to as “ASA 
resistance” or hypo-responsiveness [1-3]. Failure to respond to ASA therapy is normally a 
result of a combination of factors including genetic polymorphisms, drug interactions and 
poor compliance [4, 5]. Despite this, current guidelines do not recommend laboratory testing 
for monitoring and personalising ASA therapy [6].T2D is a pro-thrombotic state characterized 
by increased platelet reactivity and turnover, increased hepatic synthesis of fibrinogen and 
plasminogen activator inhibitor (PAI-1) and quantitative changes in the glycation and 
oxidation of clotting factors [1, 7, 8]. Accordingly, it is possible that higher or more frequent 
doses of ASA might be required to potentially overcome metabolic barriers in T2D, particularly 
in conditions where platelet turnover is increased [9].  Once-daily low dose ASA dosing may 
be, therefore, insufficient when platelet turnover is increased as irreversibly inhibited 
platelets are removed more rapidly from the circulation and replaced by new platelets not 
yet exposed to ASA [9-11].  Enteric coatings of ASA have also been shown to be an important 
variable for contributing to reduced bioavailability and poor responsiveness to ASA in T2D 
[12]. Twice daily dosing has also been advocated for treating patients with essential 
thrombocythemia as well as T2D where there is evidence of increased platelet turnover [13, 
14].  
Our recent study demonstrated that ASA 100 mg given twice daily was more effective in 
reducing platelet reactivity than 100 mg given once daily in T2D, despite showing that there 
was no evidence of increased platelet turnover in these patients [15]. The study primary 
objective was to compare changes from baseline in platelet reactivity with each of three ASA 
regimens, as measured by the VerifyNow™-ASA point-of-care test (POC) (Accumetrics, CA, 
USA)[16, 17].  Secondary objectives were to further assess changes in platelet function using 
a variety of both specialised and point-of-care COX-1 dependent/independent platelet 
function tests.  Many tests are now available for measuring inhibition of platelet function but 
they are becoming increasingly diverse and simpler to perform [18]. Although light 
transmission aggregometry (LTA) is still regarded as the gold standard despite being invented 
in the 1960’s, poor standardization and its restriction to specialised laboratories means that 
the test is limited for potential clinical utility [18]. Measurement of thromboxane and its 
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metabolites within serum and urine are important for specifically measuring the biochemical 
consequences of ASA inhibition of platelet COX-1 activity but again are both restricted to 
specialised laboratories. In the last 20 years a number of simpler semi and full point-of-care 
tests have been developed (e.g. PFA-100TM, Multiplate and VerifyNowTM) but it is still unclear 
whether these tests are actually useful for monitoring ASA in this context and how they may 
perform against LTA and Thromboxane measurements [18-20]. As we previously 
demonstrated that there were clear differences in the ability of some of these tests to detect 
differences between the 3 ASA dose regimens [15], the aim of this additional study was 
therefore to not only compare and contrast but examine in detail the performance 
characteristics of all these tests in each of the three ASA regimens used in the trial. 
 
Materials and Methods 
This investigator-led, single-centre, randomized, prospective, double-blind study received 
ethical approval from the South East London Research Ethics Committee 3 [15]. It complied 
with The World Medical Association Declaration of Helsinki (1964) and its amendments and 
clarifications, the European Union Clinical Trials Directive (2001/20/EC), and International 
Conference on Harmonisation Harmonized Tripartite Guideline for Good Clinical Practice 
(CPMP/ICH/135/95).  All participants provided written informed consent.  The authors are 
solely responsible for the design, conduct, and analysis of this study, the drafting and editing 
of the manuscript, and its final contents.   
Participants 
Twenty-four patients with T2D were recruited from local primary care clinics and from the 
Oxford Centre for Diabetes, Endocrinology, and Metabolism research recruitment register.  
Eligible participants were required to be at least 18 years of age, have no prior history of 
cardiovascular disease, be on stable diabetes therapy with diet or oral anti-hyperglycemic 
agents for at least 3 months, with HbA1c < 10% (86 mmol/mol) and triglycerides ≤2 mmol/L.  
Patients with the following conditions were excluded: pregnant or lactating; peptic ulcer 
disease or other gastro-intestinal disorder; blood pressure >150/100 mmHg; bleeding 
disorder; evidence of severe hepatic disease or ALT>3-times the upper limit of normal; severe 
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renal disease or eGFR <40ml/min/1.73m2; currently taking or with a contraindication to 
treatment with aspirin.  
Study design 
In this 3-treatment, crossover study, participants were randomized to one of six possible 
treatment sequences during which they received the identical formulation of ASA 
(acetylsalicylic acid, Bayer Pharma AG, Germany) or matching placebo as two tablets twice a 
day according to 3 different regimens with active therapy ; 100 mg once-daily, 200 mg once-
daily or 100 mg twice-daily. Each 2-week treatment period was followed by a 2-week washout 
[15].  ASA doses were chosen to approximate doses used in clinical practice and to facilitate 
the use of a double-blinded placebo control.   
 
Blood Sampling 
Fasting venous blood and urine samples were taken at baseline, and then on completion of 
each treatment period.  All samples were taken between 8 am and noon and 12 or 24 hours 
after the ingestion of the last ASA dose (depending upon the dosage regime) to minimize the 
immediate impact of ASA administration and circadian effects on platelet function.  Samples 
were transported to the local platelet laboratory by hand in upright tubes in a rack kept at 
room temperature, with platelet function testing performed > 30 minutes but within 4 hours 
of collection in keeping with British Committee for Standards in Haematology guidelines for 
platelet function testing. All samples were coded and blinded for ASA dosages. Blood samples 
for platelet function (LTA, PFA-100TM and WBA) were anticoagulated with 1/10 volume of 
3.2% trisodium citrate in vacutainers (Becton Dickinson, Oxford UK). As recommended the 2 
mL Greiner Bio-One partial-fill vacuette tube with 1/10 volume of 3.2% sodium citrate was 
used for blood samples to be tested on the VerifyNowTM-ASA. Serum samples were clotted at 
370C with a standardised incubation of 30 minutes before centrifugation at 2000 g for 20 
minutes and the serum stored at -700C until analysis. Stabilized urine samples were collected 
into universal tubes (25 ml) and stored in aliquots at 700C until analysis. EDTA vacutainers 
were used for blood counting. 
Platelet Function Testing 
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The VerifyNowTM-ASA (Accumetrics, CA, USA) test was selected as being the most convenient 
method for assessing the impact of ASA on platelet reactivity in this trial. The primary 
objective was therefore to compare changes from baseline in platelet reactivity with each of 
three ASA regimens [15].  The VerifyNow™-ASA Point-of Care test Cartridges were stored at 
40C and warmed up to room temperature before analysis. The same batch of cartridges was 
used for the entire trial. Internal quality control of the instrument was performed on each day 
of testing and test cartridges were then loaded into the instrument immediately followed by 
insertion of the mixed special citrated whole blood sample onto the needle within the 
cartridge to initiate the test. The instrument then withdraws the blood under vacuum into 
the various reaction channels of the cartridge where automated LTA is then performed using 
arachidonic acid as the agonist. After the test has finished the results were displayed and 
printed.   The results of this test, which is based on turbidimetric optical detection of platelet 
aggregation in whole blood, are expressed in ASA reactive units (ARUs), with a  lower limit of 
normal (LLN) >550 ARU.  Secondary objectives were to further assess changes in platelet 
function using a variety of COX-1 dependent and COX-1 independent platelet function tests.  
Light transmission aggregometry (LTA) was measured with a PAP-4 light transmission 
aggregometer (Biodata corporation) with 0.5 mg/mL arachidonic acid (AA) and 10 µM 
adenosine diphosphate (ADP) as agonists with unadjusted Platelet Rich Plasma (PRP) counts 
in line with recent guidelines. PRP was prepared by centrifugation of citrated whole blood by 
centrifugation at 200 g for 10 minutes and stored at room temperature in capped tubes. 
Platelet Poor Plasma (PPP) was prepared by centrifugation at 2000 g for 20 minutes. 270 l 
of PRP and PPP was pipetted into PAP-4 aggregometry tubes and a magnetic stir bar added 
to the PRP tube and the tubes incubated at 370C for 5 minutes before testing. In each channel, 
100% maximal aggregation was set with PPP and then a 0% baseline established with PRP for 
at least 2 minutes before addition of 30 l of stock agonists. The same source and batch of 
each agonist were used for the entire study and stored frozen at -700C. Arachidonic acid was 
stored frozen at 5 mg/ml in distilled water in glass vials. Before testing agonists were thawed 
and then kept on ice. Results were reported as maximal platelet aggregation after 10 minutes 
with LLN ≥20% for AA and ≥70% for ADP. Multiple electrode whole blood aggregometry (WBA) 
was performed using a 5-channel Multiplate™ aggregometer (Roche Diagnostics, Munich, 
Germany) with an integrated computer and guided automatic pipetting. Citrated whole blood 
samples were mixed gently before pipetting into disposable ready to use test cells containing 
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two independent sensor units consisting of two silver coated highly conductive copper 
electrodes and a stir-bar.  In each test cuvette, mixed whole blood was immediately diluted 
1:1 vol/vol with 0.9% saline solution at 370C for 3 minutes before addition of 30 l of each 
agonist. Final concentration of agonists were 0.5 mM AA and 6.5 µM ADP as provided by the 
manufacturer.  Results are expressed as area under the curve (AUC) with LLN >71 for AA and 
>57 for ADP as provided by the manufacturer.  The platelet function analyzer (PFA-100TM, 
Siemens Diagnostics, IL, USA) used either collagen and epinephrine (CEPI) or collagen and 
adenosine diphosphate (CADP) cartridges to measure platelet thrombus formation under 
high shear. Cartridges were stored at 40C and warmed up to room temperature before testing 
commenced and the same batch used for the entire trial. A daily quality control instrument 
check was also performed on days of testing.  0.8 ml of citrated whole blood was pipetted 
into the sample reservoir each cartridge to initiate the test. Results were reported as closure 
times (CT) in seconds with upper limit of the normal range >164 seconds for CEPI and >112 
seconds for CADP. Maximal CTs were recorded as >300 seconds.  Pharmacologic effects of 
ASA were assessed by measuring serum thromboxane B2 (TxB2) and urinary 11-dehydro-
thromboxane B2 (dTxB2).  Serum TxB2 was assayed by ELISA (R&D systems, Abingdon, UK) 
according to the manufacturer’s instructions with LLN 10 ng/mL.  Urinary dTxB2 was measured 
using ELISA (AspirinWorks Test kit, Corgenix, Peterborough, UK) according to the 
manufacturer’s instructions with LLN ≥1500 pg/mg urinary creatinine. For both assays all 
samples were diluted appropriately so that the optical densities were within the standard 
curve. Creatinine levels were measured in the pathology department at the John Radcliffe 
Hospital in Oxford.  
Statistical Analysis 
Sample size estimates based on previous VerifyNowTM-ASA Point-of Care studies suggested 
that 17 patients would be required to detect a clinically-significant 27% effect size between 
any two ASA regimens, with 90% power at the 5% significance level. A total of 24 patients 
were recruited to ensure balanced allocation to the 6 possible treatment sequences, and to 
allow for potential dropouts. The results of all platelet function tests were compared at 
baseline and after each ASA regimen using kappa statistics. Each platelet function test was 
also compared with Serum TxB2 (as a measure of the direct pharmacological action of ASA) 
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and Arachidonic Acid stimulated LTA (the perceived gold standard of platelet function testing) 
by kappa statistics and Spearman correlations. 
 
Results 
Participant Characteristics 
Participant baseline characteristics are summarized in the primary outcome paper [15]. 
Briefly, participants were mean (±1SD) age 51±7 years, BMI 31.4±7.2 kg/m2 with a median 
duration of diabetes of 2 years. Nineteen participants were treated with metformin, 6 with a 
sulfonylurea and 2 with a thiazolidinedione.  None were treated with other glucose-lowering 
therapies at any time during the study. 
For the primary objective, data from two of the 72 treatment periods were excluded because 
study medication was not taken within 24 hours of assessment (one period of ASA 200 mg 
once-daily and one of ASA 100 mg twice-daily). The same 70 treatment periods were used for 
the secondary objectives, except for urinary dehydro-thromboxane B2 analyses which were 
limited to the 67 treatment periods with the requisite data available. 
Effect of ASA dose on COX-1 dependent tests  
Figure 1 shows the distribution of results for each COX-1 dependent platelet function test at 
baseline and for each of the three ASA doses. VerifyNowTM-ASA platelet reactivity decreased 
significantly from baseline 650±19 to 448±68 with ASA 100 mg once-daily, 430±65 with 200 
mg once-daily and 416±39 with 100mg twice-daily (p all <0.0001). Modelled platelet reactivity 
was reduced to a greater extent with ASA 100 mg twice-daily versus 100 mg once-daily 
(p=0.043), but not versus 200 mg once-daily (p=0.44). ASA 200 mg once-daily did not differ 
from 100 mg once-daily (p=0.20). Interestingly there were only 2 out of 24 patients who gave 
full aggregation responses by VerifyNowTM-ASA with ASA 100 mg once-daily. This was also 
mirrored in the other tests including serum TxB2 and urinary dTxB2, PFA-100TM-CEPI and CADP 
but only 1 of the 2 still gave full aggregation with LTA-AA. Only 1 of these patients then gave 
a full response by VerifyNowTM-ASA with ASA 200 mg once daily but this was still consistent 
with serum TxB2 and urinary dTxB2, PFA-100TM-CEPI and CADP and LTA-AA. However, at ASA 
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100 mg twice daily all platelet function was inhibited in this individual except PFA-100TM-CEPI. 
This could have been caused by true “ASA resistance” and/or poor compliance that was 
eventually overcome by ASA 100 mg twice daily. A failure to comply with the ASA dosage 
regime was felt unlikely in this individual as pill counts and interviews were performed and 
that both the serum TxB2 and urinary dTxB2 levels were still significantly reduced from 
baseline levels but above the accepted cut off values for these assays. The other COX-1 
dependent platelet function tests also showed significant decreases from baseline with all 
three ASA regimens (p <0.0001). The generalized mixed model demonstrated that, compared 
to ASA 100 mg once-daily, ASA 100 mg twice-daily produced statistically significant reductions 
from baseline for all COX-1 dependent platelet function tests except LTA-AA. There was no 
statistical difference for COX-1 dependent tests between ASA 100 mg twice-daily and 200 mg 
once-daily. Furthermore, ASA 200 mg once daily more effectively reduced WBA-AA than 100 
mg once-daily. Pharmacologic suppression of COX-1 activity compared to baseline was 
demonstrated at all ASA doses, as measured by decreased serum TxB2 and urinary dTxB2.  A 
greater pharmacologic effect was observed with ASA 100 mg twice-daily compared to 100mg 
one-daily for urinary dTxB2 (p=0.048) with a similar but non-significant trend for serum TxB2.  
Effect of ASA dose on non-COX-1 dependent tests 
Figure 2 shows the distribution of results for each non-COX-1 dependent platelet function test 
at baseline and for each of the 3 ASA doses. Neither the PFA-100TM-CADP nor the WBA-ADP 
platelet function tests showed any significant reduction from baseline. ASA 100 mg twice-
daily produced a greater effect on PFA-100TM-CEPI compared to 100 mg once-daily, but no 
such difference was observed with any other COX-1 independent test. There were no 
statistical differences for any COX-1 independent test between ASA 100 mg twice-daily and 
200 mg once-daily.  
Kappa Statistics 
The overall kappa statistic classifications for baseline and all ASA dosages are shown in Table 
1. No differences were observed with each test for each ASA dose.  
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Comparison with serum TxB2 
Figure 3 shows the scatter plots comparing each test with serum TxB2 and shows the results 
for baseline and the 3 ASA dosage regimens. In general COX-1 dependent tests not only 
correlated better with serum TxB2 than non-COX-1 dependent tests but gave better 
agreement.  
Comparison with LTA-AA 
Figure 4 shows the scatter plots comparing each test with LTA-AA and shows the results for 
baseline and the 3 ASA dosage regimes. 
 
Discussion 
Full details of the primary outcomes of the trial have been previously published, showing that 
100 mg of ASA twice-daily in T2D reduced platelet reactivity more effectively than 100 mg 
once-daily, and numerically more than 200 mg once-daily [15]. This regimen was also the 
most effective based on the pharmacologic effect on serum and urinary TxB2 levels, and for 
reducing platelet reactivity as measured by a number of platelet function tests, i.e. 
VerifyNowTM-ASA, WBA-AA and PFA-100TM-CEPI.  
We have now compared the secondary outcome results by comparing the performance of all 
nine different platelet function assays used in this trial.  As this trial was a small study in 24 
patients it was not feasible to measure the clinical efficacy of each test for prevention of 
ischaemic events. However, It is clear that the different platelet function tests evaluated are 
not equally effective in measuring the antiplatelet effects of ASA in T2D. The COX-1 
dependent tests (e.g. VerifyNowTM-ASA, LTA-AA and Serum TxB2) in general not only 
performed much better in correctly identifying patients at baseline and on 3 different dosages 
of ASA (Figures 1 and 2) but also correlated better with serum TxB2 levels and LTA-AA than 
non-COX 1 dependent tests (Figure 3).  The incidence of ASA non-responders is therefore also 
much lower in COX-1 dependent tests at all doses of ASA.  As all the assays used in this study 
measure different aspects of platelet function, the observed differences between the tests is 
unsurprising and confirms the results from previous studies comparing the results from these 
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tests in different types of patients receiving either ASA and/or P2Y12 inhibitors [21-24]. One of 
the major limitations of these tests is the use of cut-off values that have not been clinically 
validated and are either arbitrarily defined or established upon the responsiveness of normal 
individuals to ASA either if given in vivo or added to blood in vitro. The VerifyNowTM-ASA test 
is the only true FDA approved POC assay used in this trial and has been shown in some studies 
to relate to clinical outcomes [25, 26]. The advantage of this whole blood cartridge-based test 
is that it can be potentially used by non-platelet specialists away from the laboratory and does 
not require any pipetting of the blood sample during testing.  As this test is now widely used, 
it is therefore important that the test is also validated against a range of tests as previous 
studies have shown variable results. In this study the overall agreement with either LTA-AA (k 
= 0.95, Figure 4) (the perceived gold standard) or Serum TxB2 levels (k = 0.85, Figure 3) (a 
measure of pharmacological inhibition) was very good and it performed better than in other 
studies directly comparing these tests in different populations of patients [23, 24]. Given that 
the test now uses arachidonic acid, one would expect a reasonable correlation with other 
tests using the same agonists. The test was also performed in a specialist laboratory (and not 
as a POC test) at exactly the same time as other platelet function tests within locally taken 
fresh samples within a defined window of time and within a controlled clinical trial in a 
relatively homogeneous group of T2D patients. Some of the older comparisons of 
VerifyNowTM-ASA were also performed using cartridges that utilised a different agonist (e.g. 
propyl gallate and not arachidonic acid) which may explain some of the previous reported 
differences [17, 27].  
Of the other assays used in this study LTA-AA is still considered as the historical gold standard 
of platelet function testing [18]. As the assay also used arachidonic acid to drive platelet 
activation and aggregation it should be reasonably specific for measuring COX-1 activity as 
TxA2 generation is a critical for amplification of initial platelet activation to drive secondary 
aggregation. Indeed, as one might expect LTA-AA not only agreed very well with serum TxB2 
measurements (k = 0.83) but also VerifyNowTM-ASA (k = 0.95), the latter assay using the same 
agonist.  However, despite its good performance in this study its major disadvantage is that it 
is a specialist test and therefore can only be used by operators with expertise in performing 
this test. We also used ADP as an agonist as this has been widely used to measure ASA 
responses by LTA. As ADP stimulation is not specific for measuring COX-1 activity, low 
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concentrations of ADP (< 10 M) still require COX-1 activity for full aggregation responses to 
occur. Higher concentrations of ADP (> 10 M) are thought to be COX-1 independent so there 
is a debate over which concentrations of ADP are optimal for measuring ASA inhibition. 
Indeed in this study we chose an intermediate concentration of 10 M ADP, as we have 
previously shown that ASA does inhibit secondary aggregation responses at this dose. It is 
probably not surprising that the overall performance was therefore moderate and with 
hindsight a lower concentration of  5 M ADP could have been used instead, which has been 
shown to perform better than higher concentrations for monitoring ASA [24]. As LTA is 
performed in PRP we also wanted to compare results with whole blood aggregometry as this 
is not only  used in the VerifyNowTM-ASA test but is argued to be more physiological and does 
not require centrifugation steps to prepare samples for testing. WBA using the Multiplate 
system has also become an established test for monitoring P2Y12 antagonists as this 
instrument uses disposable cuvettes and because of its ease of use has also been used as a 
POC test within intensive care settings [28]. In this study WBA using either AA or ADP as the 
agonists gave either a moderate or poor performance respectively.  Although whole blood is 
probably more physiological the results are probably not surprising given that alternative 
mechanisms of platelet activation are highly likely to occur within whole blood which could 
potentially bypass any ASA inhibition of COX-1 activity.  The PFA-100TM also utilises whole 
blood but does not measure platelet function in the same way as classical or whole blood 
aggregometry [19]. Instead, the instrument measures high shear dependent platelet 
thrombus formation in real time which could be argued to be more physiological and is rapid 
and simple to use. Again the test is FDA approved for measuring platelet dysfunction and has 
been widely used to detect ASA responses within the CEPI cartridge but not the CADP 
cartridge which has been previously shown to be relatively insensitive to ASA [29]. Indeed in 
this study the CEPI cartridge performed either moderately or good in comparison with ASA 
dose and serum TxB2 measurements respectively. In contrast, the CADP cartridge performed 
poorly as expected. Previous studies have shown that the PFA-100TM CEPI cartridge can 
sometimes be totally insensitive to ASA and be effectively by-passed in conditions where 
there is platelet hyper-reactivity and/or high von Willebrand factor (VWF) levels, which are 
known to be elevated in patients with coronary artery disease or T2D [30]. This can even occur 
when COX-1 activity is effectively blocked by ASA as assessed by TxA2 measurements in the 
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same samples.   There was some evidence of normal closure times in this study particularly 
at the lower doses of ASA even though TxA2 levels suggested there was effective inhibition of 
COX-1. It could be that the VWF levels may have been higher in some individuals as this is an 
important variable for determining efficient platelet adherence to collagen and aggregation 
under the high shear conditions in the test. Unfortunately, VWF levels were not measured in 
this study but have been shown to contribute to normal closure times in other studies where 
poor responsiveness to ASA was observed [31].  
As TxB2 is the major metabolite of platelet derived TxA2 in plasma/serum then this provides a 
direct and specific biochemical measurement of the effect of ASA on COX-1 activity. The 
presence of the thromboxane metabolite dTxB2 in the urine can also be directly correlated 
with platelet activation and inhibition of COX-1 and thromboxane generation by ASA. In this 
study, however dTxB2 only gave a moderate correlation with serum TxB2 levels. As dTxB2 is 
being measured in urine from patients and unlike serum TxB2 is not being generated ex vivo, 
this provides a global measurement of TxA2 which could originate from other cellular sources 
as well as platelets [24]. Again these results are therefore unsurprising and are supported by 
previous studies that report discrepancies between platelet derived TxB2 and urinary dTxB2.  
In summary in this study we have shown that not all platelet function tests used for 
monitoring ASA therapy in TD2 are equivalent and therefore the results are not 
interchangeable.  As one might have predicted, platelet function tests that specifically 
measured COX-1 pathway (e.g. VerifyNow™-ASA, LTA-AA and Serum TxB2) were more 
sensitive in detecting ASA inhibition in general, although there were clear differences in 
responsiveness between different doses which is probably related to T2D and not the efficacy 
of the COX-1 dependent tests themselves. 
Although routine ASA monitoring is not currently recommended, personalising ASA therapy 
in high risk patients (e.g. T2D) as shown in this trial may have potential benefit providing COX-
1 dependent tests were used [15]. This would certainly have to be confirmed in large 
prospective studies to study clinical outcomes and whether there is any increased risk in 
bleeding with higher dosages of ASA especially over more prolonged periods of treatment.  
Current guidelines also suggest that P2Y12 inhibitors should also not be monitored except 
perhaps again in high risk individuals , so any role for personalising antiplatelet therapy with 
14 
 
platelet function testing is still very uncertain.  Future trials should also distinguish between 
measuring the in vitro efficacy of ASA versus clinical efficacy and prevention of ischemic 
events. It is likely that true “ASA resistance” is rare and often caused by poor compliance but 
underlying platelet hyper-reactivity can often increase the risk of thrombosis despite effective 
COX-1 inhibition by ASA [6, 32]. 
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Figure Legends 
Figure 1. Distribution of COX-1 dependent platelet function test results by each test for 
baseline (blue) and each ASA dose (100 mg (green), 200 mg (black) and 100 mg x 2 (red)). A – 
VerifyNowTM-ASA (ARU), B – LTA (AA) (%), C – WBA (AA) (AUC), D – Serum TxB2 (ng/ml) and E 
– Urinary dTxB2 (pg/ml). Platelet reactivity was significantly decreased (P< 0.0001) in all tests 
at each ASA dose compared to baseline. Any significant differences between ASA dosages in 
each test are shown. 
Figure 2. Distribution of non-COX-1 dependent platelet function test results by each test for 
baseline (blue) and each ASA dose (100 mg (green), 200 mg (black) and 100 mg x 2 (red)). A – 
PFA-100TMCEPI (seconds), B – PFA-100TM-CADP (seconds), C – LTA (ADP) and D – WBA (ADP) 
(AUC). Dotted lines denote the cut-off values for each test.  Platelet reactivity was significant 
decreased (P < 0.0001) in the PFA-100TMCEPI and LTA (ADP) tests at each ASA dose compared 
to baseline but not in the PFA-100TM-CADP and WBA (ADP) tests. Any significant differences 
between ASA dosages in each test are shown. 
 
Figure 3. Scatterplots comparing all platelet function tests with serum TxB2 levels (ng/ml). 
Baseline values are shown as blue dots, 100 mg ASA as green squares, 200 mg ASA as black 
triangles and 100 mg x 2 ASA as red squares. A – VerifyNowTM-ASA(ARU), B – LTA (AA) (%), C 
– WBA (AA) (AUC), D – Urinary dTxB2 (pg/ml), E – PFA-100TM-CEPI (seconds), F – LTA (ADP), G 
– PFA-100TMCADP (seconds) and H – WBA (ADP) (AUC). The solid lines denote the cut-off 
values for each test. 
Figure 4. Scatterplots comparing all platelet function tests with LTA-AA (%). Baseline values 
are shown as blue dots, 100 mg ASA as green squares, 200 mg ASA as black triangles and 100 
mg x 2 ASA as red squares. A – VerifyNowTM-ASA (ARU), B – LTA (AA) (%), C – Serum TxB2 
(ng/ml), D – Urinary dTxB2 (pg/ml), E – PFA-100TMCEPI (seconds), F – LTA (ADP), G – PFA-
100TMCADP (seconds) and H – WBA (ADP) (AUC). The solid lines denote the cut-off values for 
each test. 
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Table 1. Overall kappa statistic classifications for each platelet function test at baseline with either all or each individual ASA dosage regime. 
Values 0–0.20 are classified as poor, 0.21–0.40 fair, 0.41–0.60 as moderate, 0.61–0.80 as good, and 0.81–1 as very good. 
 
 
 
 
 
 
 
ASA Dose VerifyNowTM-
ASA 
LTA-
AA 
WBA-
AA 
LTA-
ADP 
WBA-
ADP 
PFA-100TM 
CEPI 
PFA-100TM 
CADP 
Serum 
TxB2 
Urine 
TxB2 
all 0.85 0.95 0.47 0.59 -0.07 0.56 -0.02 0.79 0.55 
100 mg OD 0.91 0.96 0.41 0.49 -0.10 0.57 -0.08 0.74 0.62 
200 mg OD 0.92 0.96 0.42 0.46 0.04 0.67 0.00 0.88 0.63 
100 mg BD  0.96 1.00 0.42 0.46 0.25 0.79 0.04 0.96 0.67 
